Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of Akero Therapeutics (NASDAQ:AKRO – Free Report) in a report issued on Monday,Benzinga reports. The brokerage currently has a $50.00 target price on the stock. Separately, Citigroup began coverage on shares of Akero Therapeutics in a research report on Monday. They set a “buy” rating and a […]
More Stories
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ) Sees Significant Increase in Short Interest
BlackRock Innovation and Growth Term Trust (NYSE:BIGZ – Get Free Report) was the recipient of a significant increase in short...
Analysts’ Recent Ratings Updates for Arch Resources (ARCH)
Several analysts have recently updated their ratings and price targets for Arch Resources (NYSE: ARCH): 11/19/2024 – Arch Resources is...
Verity & Verity LLC Raises Position in American Express (NYSE:AXP)
Verity & Verity LLC increased its holdings in shares of American Express (NYSE:AXP) by 2.5% during the 3rd quarter, according...
Caldwell Investment Management Ltd. Makes New $995,000 Investment in Oracle Co. (NYSE:ORCL)
Caldwell Investment Management Ltd. acquired a new stake in Oracle Co. (NYSE:ORCL – Free Report) in the 3rd quarter, according...
Fortis Advisors LLC Increases Position in iShares Core Dividend Growth ETF (NYSEARCA:DGRO)
Fortis Advisors LLC boosted its holdings in iShares Core Dividend Growth ETF (NYSEARCA:DGRO – Free Report) by 96.7% in the...
The Coca-Cola Company (NYSE:KO) Shares Sold by Belmont Capital LLC
Belmont Capital LLC lessened its holdings in shares of The Coca-Cola Company (NYSE:KO – Free Report) by 91.3% in the...